LSV Asset Administration grew its place in Exelixis, Inc. (NASDAQ:EXEL – Get Ranking) by 13.4% within the third quarter, in line with its most up-to-date disclosure with the SEC. The fund owned 2,035,098 shares of the biotechnology firm’s inventory after shopping for a further 241,137 shares throughout the interval. LSV Asset Administration owned roughly 0.63% of Exelixis price $31,910,000 as of its most up-to-date SEC submitting.
A number of different hedge funds have additionally just lately made adjustments to their positions within the inventory. M&T Financial institution Corp raised its stake in Exelixis by 5.1% throughout the second quarter. M&T Financial institution Corp now owns 10,506 shares of the biotechnology firm’s inventory valued at $208,000 after buying a further 514 shares within the final quarter. Fulton Financial institution N.A. elevated its holdings in shares of Exelixis by 6.3% throughout the third quarter. Fulton Financial institution N.A. now owns 10,765 shares of the biotechnology firm’s inventory valued at $169,000 after buying a further 640 shares within the final quarter. CWM LLC grew its stake in Exelixis by 12.8% within the third quarter. CWM LLC now owns 6,053 shares of the biotechnology firm’s inventory valued at $95,000 after buying a further 687 shares throughout the interval. US Bancorp DE grew its stake in Exelixis by 1.1% within the third quarter. US Bancorp DE now owns 75,522 shares of the biotechnology firm’s inventory valued at $1,184,000 after buying a further 786 shares throughout the interval. Lastly, Securian Asset Administration Inc. boosted its stake in Exelixis by 3.0% throughout the 2nd quarter. Securian Asset Administration Inc. now owns 29,240 shares of the biotechnology firm’s inventory price $609,000 after buying a further 851 shares over the past quarter. 84.74% of the inventory is owned by hedge funds and different institutional traders.
Wall Road Analysts Forecast Progress
A number of analysis analysts have just lately weighed in on the inventory. StockNews.com began protection on shares of Exelixis in a analysis report on Wednesday, October twelfth. They set a “purchase” ranking on the inventory. Truist Monetary reduce their goal worth on shares of Exelixis from $35.00 to $32.00 in a analysis word on Friday, December ninth. EF Hutton Acquisition Co. I lowered their worth goal on Exelixis from $28.00 to $24.00 and set a “purchase” ranking for the corporate in a report on Wednesday, January eleventh. JMP Securities lowered their worth goal on Exelixis from $25.00 to $24.00 and set a “market outperform” ranking for the corporate in a report on Thursday, January nineteenth. Lastly, Morgan Stanley decreased their worth goal on Exelixis from $23.00 to $22.00 and set an “equal weight” ranking for the corporate in a report on Wednesday, November 2nd. One analysis analyst has rated the inventory with a maintain ranking and 9 have assigned a purchase ranking to the inventory. Based on knowledge from MarketBeat.com, the inventory at the moment has a consensus ranking of “Reasonable Purchase” and a median goal worth of $27.58.
Exelixis Inventory Down 0.3 %
EXEL inventory opened at $17.56 on Thursday. Exelixis, Inc. has a 52-week low of $14.87 and a 52-week excessive of $23.40. The inventory’s 50 day transferring common is $16.54 and its two-hundred day transferring common is $17.40. The corporate has a market capitalization of $5.66 billion, a PE ratio of 18.48, a P/E/G ratio of 0.59 and a beta of 0.72.
Exelixis (NASDAQ:EXEL – Get Ranking) final issued its earnings outcomes on Tuesday, November 1st. The biotechnology firm reported $0.23 EPS for the quarter, topping the consensus estimate of $0.18 by $0.05. Exelixis had a return on fairness of 13.11% and a web margin of 18.78%. The corporate had income of $411.74 million throughout the quarter, in comparison with analyst estimates of $404.15 million. As a bunch, sell-side analysts anticipate that Exelixis, Inc. will put up 0.53 EPS for the present yr.
Insiders Place Their Bets
In different information, Director George Poste bought 40,000 shares of the enterprise’s inventory in a transaction on Tuesday, November twenty ninth. The inventory was bought at a median worth of $16.68, for a complete worth of $667,200.00. Following the sale, the director now owns 193,189 shares of the corporate’s inventory, valued at roughly $3,222,392.52. The transaction was disclosed in a doc filed with the Securities & Alternate Fee, which will be accessed by this hyperlink. In associated information, Director George Poste bought 40,000 shares of the inventory in a transaction dated Tuesday, November twenty ninth. The inventory was bought at a median worth of $16.68, for a complete worth of $667,200.00. Following the completion of the sale, the director now straight owns 193,189 shares of the corporate’s inventory, valued at roughly $3,222,392.52. The sale was disclosed in a doc filed with the SEC, which will be accessed by this hyperlink. Additionally, EVP Peter Lamb bought 20,000 shares of the inventory in a transaction dated Thursday, December fifteenth. The inventory was bought at a median worth of $15.88, for a complete worth of $317,600.00. Following the completion of the sale, the chief vp now straight owns 410,958 shares of the corporate’s inventory, valued at $6,526,013.04. The disclosure for this sale will be discovered right here. 2.90% of the inventory is at the moment owned by insiders.
About Exelixis
Exelixis, Inc is a biopharmaceutical firm, which engages within the growth, commercialization, and discovery of recent medicines for the therapy of most cancers. It gives merchandise underneath the manufacturers of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The corporate was based by Corey S. Goodman and Stelios B.
Featured Articles
This on the spot information alert was generated by narrative science expertise and monetary knowledge from MarketBeat to be able to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial group previous to publication. Please ship any questions or feedback about this story to [email protected].
Earlier than you contemplate Exelixis, you will need to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and finest performing analysis analysts and the shares they advocate to their purchasers each day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Exelixis wasn’t on the listing.
Whereas Exelixis at the moment has a “Reasonable Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.
